The role of vitamin B1-B2 and plasma lipid profile in intrahepatic cholestasis of pregnancy

Başaranoğlu, Serdar; Ağaçayak, Elif; Uçmak, Feyzullah; Tunç, Senem Yaman; Deregözü, Ayşegül; Akkurt, Zeynep Meltem; Peker, Nurullah; Acet, Mustafa; Yüksel, Hatice; Gül, Talip

doi:10.1515/jpm-2015-0337

Cited by 10 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It affects~0.3 to 5.6% of pregnancies and has ethnic, geographic, and seasonal variation. 17 China is a high-prevalence area of ICP, where the incidence rate can reach 2.3 to 10.0%, 18 resulting in a great threat to maternal and child health. To the best of our knowledge, only a few studies have reported the association of ICP with abnormal lipid profiles.…”

mentioning

confidence: 99%

Associations between Maternal Lipid Profiles and Pregnancy Complications: A Prospective Population-Based Study

et al. 2019

View full text Add to dashboard Cite

Objective To investigate whether plasma lipid profiles are independently associated with pregnancy complications including gestational diabetes mellitus (GDM), hypertensive disorder complicating pregnancy (HDCP), and intrahepatic cholestasis of pregnancy (ICP). Study Design A prospective study was conducted among 1,704 pregnant women at three medical institutions in Chengdu, China. The concentrations of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured at gestational weeks 12 ± 1, 24 ± 1, and 34 ± 1. Logistic regression models were used to estimate the association between lipid profiles and pregnancy complications. Receiver operating characteristic analysis was performed to determine the value of lipid profiles to predict GDM and HDCP. Results After adjusting for potential confounders, TG, TC, and LDL-C in the first trimester were independently associated with GDM (TG: odds ratio [OR] =2.00, 95% confidence interval [CI]: 1.57–2.56; TC: OR = 1.38, 95% CI: 1.16–1.64; LDL-C: OR = 1.43, 95% CI: 1.14–1.79) and HDCP (TG: OR = 2.42, 95% CI: 1.56–3.78, TC: OR = 1.64, 95% CI: 1.04–2.57; LDL-C: OR = 1.87, 95% CI: 1.07–3.25). The TC concentration during the whole pregnancy (first trimester: OR = 1.53, 95% CI: 1.13–2.08; second trimester: OR = 1.31, 95% CI: 1.06–1.61; third trimester: OR = 1.39, 95% CI: 1.17–2.04) and LDL-C in the last two trimesters (second trimester: OR = 1.62, 95% CI: 1.30–2.04; third trimester: OR = 1.56, 95% CI: 1.29–1.88) were positively associated with ICP. HDL-C in the third trimester was negatively associated with the risk of ICP (OR = 0.46, 95% CI: 0.22–0.98). Combining lipid profiles in the first trimester with the other common predictors to predict GDM or HDCP owned stronger predictive power with the largest area under the curve (GDM: 0.643 [95% CI: 0.613–0.673], HDCP: 0.707 [95% CI: 0.610–0.804]) than either indicator alone. Conclusion Maternal lipid profiles during the whole pregnancy are significantly associated with GDM, HDCP, and ICP. Combining lipid profiles in the first trimester with the other common predictors could effectively improve the power of predicting GDM and HDCP.

show abstract

mentioning

confidence: 99%

Associations between Maternal Lipid Profiles and Pregnancy Complications: A Prospective Population-Based Study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…After duplicates were removed, the titles and/or abstracts of the 278 references were carefully screened. After that assessment, 11 studies met the inclusion criteria and were included in the qualitative analysis 11,14–23 . Finally, nine studies were included in the final meta‐analysis, with all nine reporting TG, TC and HDL cholesterol data and eight reporting LDL cholesterol data (Figure 1).…”

Section: Resultsmentioning

confidence: 99%

“…Among the 11 included studies, one was a prospective case–control study 17 and 10 were cohort studies, including seven prospective cohort studies 14,16,18–22 . Study quality was assessed using the modified NOS.…”

Section: Resultsmentioning

confidence: 99%

Intrahepatic cholestasis of pregnancy and maternal dyslipidemia: a systematic review and meta‐analysis

Zhan

Chen

et al. 2022

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Introduction:The association between intrahepatic cholestasis of pregnancy (ICP) and maternal lipid metabolism remains unknown. This systematic review and metaanalysis aimed to evaluate the association between ICP and maternal lipid metabolism. Material and methods:We systematically searched Medline, Embase and the Cochrane Library (up to December 11, 2021) to identify relevant studies that investigated ICP and maternal plasma lipid concentrations. The weighted mean difference (WMD) and 95% confidence intervals (CI) were calculated using random-effects models. A subgroup analysis was conducted to identify the potential sources of heterogeneity. Potential publication bias was tested using funnel plots and the Egger's and Begg's tests. This meta-analysis was registered with PROSPERO (CRD42021293783).Results: Eleven studies were included in this qualitative analysis. A random-effects meta-analysis of data from the final included nine studies (n = 786 participants) showed a significant association between ICP and maternal dyslipidemia, with elevated levels of triglycerides (WMD, 0.

show abstract

“…However, abnormal elevations in plasma triacylglycerol levels during pregnancy have been associated with gestational hypertension and preeclampsia, and may be related to preterm births and macrosomic babies ( Vrijkotte et al, 2012 ). In humans, abnormal elevations in triacylglycerol levels during late gestation commonly correlate with excess weight and obesity ( Farias et al, 2016 ), sedentarism ( Monda et al, 2009 ), smoking ( Gastaldelli et al, 2010 ), vitamin D deficiency ( Başaranoğlu et al, 2017 ), and use of some medications (i.e., beta blockers, valproate, and sertraline; Wild et al, 2016 ) in mothers.…”

Section: Introductionmentioning

confidence: 99%

Dexamethasone Administration During Late Gestation Has No Major Impact on Lipid Metabolism, but Reduces Newborn Survival Rate in Wistar Rats

et al. 2018

View full text Add to dashboard Cite

A rise in plasma triacylglycerol levels is a common physiological occurrence during late gestation and excess of glucocorticoids (GCs) has been shown to impair lipid metabolism. Based on those observations, we investigated whether the administration of dexamethasone during the late gestational period could exacerbate this pregnancy associated hypertriacylglycerolemia in rats. For this, female Wistar rats were treated with dexamethasone (0.2 mg/kg of body mass in the drinking water on days 14–19 of pregnancy; DP group) or equivalent days in the virgin rats (DV group). Untreated pregnant rats (control pregnant group) and age-matched virgin rats (control virgin group) were used as controls. Functional, biochemical, and molecular analyses were carried out after treatment with GC and in the control groups. Euthanasia was performed on day 20 of pregnancy. The metabolic parameters of the mothers (dams) at the time of weaning and 6 months later, as well as newborn survival, were evaluated. We observed that neither dexamethasone nor pregnancy affected blood glucose or glucose tolerance. Hypertriacylglycerolemia associated with lipid intolerance or reduced hepatic triacylglycerol clearance was observed during the late gestational period. GC treatment caused a further increase in basal plasma triacylglycerol levels, but did not have a significant effect on lipid tolerance and hepatic triacylglycerol clearance in pregnant rats. GC, but not pregnancy, caused few significant changes in mRNA expression of proteins involved in lipid metabolism. Dexamethasone during pregnancy had no impact on lipid metabolism later in the dams’ life; however, it led to intra-uterine growth restriction and reduced pup survival rate. In conclusion, GC exposure during the late gestational period in rats has no major impact on maternal lipid homeostasis, soon after parturition at weaning, or later in the dams’ life, but GC exposure is deleterious to the newborn when high doses are administered at late gestation. These data highlight the importance of performing an individualized and rigorous control of a GC treatment during late pregnancy considering its harmful impact on the fetuses’ health.

show abstract

The role of vitamin B1-B2 and plasma lipid profile in intrahepatic cholestasis of pregnancy

Cited by 10 publications

References 26 publications

Associations between Maternal Lipid Profiles and Pregnancy Complications: A Prospective Population-Based Study

Associations between Maternal Lipid Profiles and Pregnancy Complications: A Prospective Population-Based Study

Intrahepatic cholestasis of pregnancy and maternal dyslipidemia: a systematic review and meta‐analysis

Dexamethasone Administration During Late Gestation Has No Major Impact on Lipid Metabolism, but Reduces Newborn Survival Rate in Wistar Rats

Contact Info

Product

Resources

About